As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate

 
• By Cole Werble

Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.

gene and color background
• Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies